WO2010139678A1 - Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms - Google Patents

Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms Download PDF

Info

Publication number
WO2010139678A1
WO2010139678A1 PCT/EP2010/057598 EP2010057598W WO2010139678A1 WO 2010139678 A1 WO2010139678 A1 WO 2010139678A1 EP 2010057598 W EP2010057598 W EP 2010057598W WO 2010139678 A1 WO2010139678 A1 WO 2010139678A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutically acceptable
methyl
alpha
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/057598
Other languages
English (en)
French (fr)
Inventor
Claudiu Supuran
Seppo Parkkila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tampereen Yliopisto
Original Assignee
Tampereen Yliopisto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tampereen Yliopisto filed Critical Tampereen Yliopisto
Priority to JP2012513590A priority Critical patent/JP2012528824A/ja
Priority to EP10722356.2A priority patent/EP2437745B1/en
Priority to US13/375,946 priority patent/US9623025B2/en
Publication of WO2010139678A1 publication Critical patent/WO2010139678A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to 4-(4-methylpiperazin-1-yimethyl)-'N- ⁇ 4-methyl-3- ⁇ 4-pyrJdin «3- yl)pyrim»dirv2-ylamino)phenylB>enzamide (also known as "imatinib” [International Nonproprietary Name)) and 4 ⁇ methyl-3-t[4-(3-pyridinyt)-2-pyrimidinyl]amino]-W ⁇ [5-(4-methyl-1H- imidazoM-yl)-3-(trifluoromethyl)phenyl] benzamide (also known as "nilotinib” [International Non-proprietary Name ⁇ ) or pharmaceutically acceptable salts thereof, respectively, for the treatment of disorders mediated by alpha-carbonic anhydrase isoforms, to the use of imatinib and niJotinib or pharmaceutically acceptable salts thereof, respectively, in the treatment of disorders mediated by alpha-carbonic anhydrase isoforms,
  • Inhibitors of carbonic anhydrase are used for the treatment of intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, migraine, headaches, gastric and duodenal ulcers, neurological disorders and osteoporosis (Supuran, CT. , Scozzafava, A., Conway, J. (Eds): Carbonic anhydrase - Its inhibitors and activators, CRC Press, Boca Raton (FL), USA, 2004, pp. 1-363; Supuran, C.T., Scozzafava, A., Carbonic anhydrase inhibitors and their therapeutic potential, Expert OpIn. Ther.
  • CA inhibitors such as topiramate and zonisamide are also effective as antiobesity agents although they are not currently approved for such a use (Supuran, Nature Rev Drug Discov 2008).
  • Imatinib (as mesylate salt, GlivecTM/GIeevecTM) blocks the activity of the Bcr-Abl oncoprotein and the cell transmembrane tyrosine kinase receptor c-Kit.
  • GlivecTM is approved for several indications including the treatment on chronic myeloid leukemia (CML) and gastrointestinal stroma ⁇ tumors (GIST).
  • Nilotinib (TasignaTM) is a second-generation protein tyrosine kinase inhibitor (PTKI) and was approved in 2007 for the treatment of adult patients with chronic- phase and accelerated-phase Philadelphia chromosome-positive (Ph+) CML, resistant to or intolerant of prior treatment that included imatinib.
  • the compound is also being investigated for the treatment of patients with GIST. It has now been demonstrated, surprisingly, that imatinib mesylate and nilotinib hydrochloride monohydrate inhibit all 13 catalytically active mammalian isoforms CA I - XV with K
  • the PTKIs imatinib and nilotinib act as very potent inhibitors of two CA isozymes, i.e., human CA I ⁇ hCA I) and Il (hCA II), with inhibition constants in the range of 4.1 - 31,9 nM,
  • the Jsoform with the highest affinity for these two compounds is the ubiquitous, physiologically dominant hCA II.
  • acetazolamide has a K, of 12 nM against hCA Ii, intermediate between that of niiotinib (Ki of 4.1 nM) and imatinib (K 1 of 30.2 nM).
  • hCA I The second cytosolic isoform, hCA I, also shows high affinities for both compounds ⁇ K,s of 29.3 - 31.9 nM), although the K t values are an order of magnitude tower than that of acetazolamide. Importantly, the results show that nilotinib is a slightly better hCA I and Ii inhibitor compared to imatinib.
  • a third group of CA isozymes including hCA lit (cytosolic), Vl (secreted in saliva and milk), Xii (transmembrane, present in some tumors among other tissues) and XIV (transmembrane) are moderately inhibited by imatinib and nilotinib, with K 1 S in the range of 223 - 980 nM.
  • the membrane-bound hCA IV is also inhibited moderately by nilotinib (K 1 of 446 nM) but much less by imatinib (K 1 of 4553 nM, Table 1 , below).
  • the present invention relates to imatinib and nilotinib, or pharmaceutically acceptable salts thereof, respectively, for treating disorders mediated by alpha-carbonic anhydrase isoforms.
  • disorders mediated by alpha-carbonic anhydrase isoforms denotes (a) intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, migraine, headaches, gastric and duodenal ulcers, neurological disorders, obesity, and osteoporosis, and (b) cancers, especially hypoxic tumors and other cancers, in which CA i I, CA IX or CA XII is overexpressed.
  • the present invention relates to the treatment of intraocular hypertension (glaucoma).
  • the present invention relates to cancers, in which CA Il is expressed.
  • CA Il expression has been reported in various benign tumors such as meningioma (Korhonen, K. et al. J. Neurosurg. 2009, Feb 13. [Epub ahead of print]) and cancers such as pancreatic carcinoma (Parkkila, S. et al. Histochem, J. 1995, 27, 133), glioma (Haapasalo, J. et al., Neuro Oncol.
  • the present invention also provides for imatinib or niiotinib, or pharmaceutically acceptable salts thereof, respectively, for treating a cancer selected from GIST, CML, meningioma, pancreatic carcinoma, glioma, melanoma, acute myeloid leukemia, and acute lymphoblastic leukemia, wherein the cancer is mediated by CA II.
  • the present invention relates to the treatment of tumors, especially hypoxic tumors, in which CA IX and/or CA XII is overexpressed.
  • treatment means curative treatment and prophylactic treatment.
  • the preparation of imatinib and its use, especially as an anti-tumor agent, are described in Example 21 of EP-A-O 564 409 and US 5,521 ,184, both incorporated by reference.
  • Pharmaceutically acceptable salts of imatinib are pharmaceutically acceptable acid addition salts, tike for example with inorganic acids, such as hydrochloric add, sulfuric acid or a phosphoric acid, or with suitable organic carboxylic or sulfonic acids, for example aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic acid, succinic acid, mateic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric add, citric acid or oxalic acid, or amino acids such as arginine or lysine, aromatic carboxyiic acids, such as benzoic acid, 2-phenoxy-benzoic acid, 2 ⁇ acetoxy-benzoic acid, salicylic acid, 4- aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or is
  • the monomethanesulfonic acid addition salt of imatinib also Known as "imatinib mesylate" and preferred crystal forms thereof , e.g. the ⁇ -crystai form, are described in WO99/03854.
  • effective doses for example oral daily doses of about 100-1000 mg, preferably 200-600 mg, especially 400 mg of imatinib, are administered to warm-blooded animals of about 70 kg body weight.
  • a starting dose corresponding to 400 mg of imattnrb I free base daily can be recommended for oral delivery.
  • Nilotinib and the process for its manufacture are disclosed in WO 04/005281 which is incorporated by reference, Pharmaceutically acceptable salts of nilotinib are especially those disclosed in WO2007/015871.
  • niiotinib is employed in the form of its hydrochloride monohydrate.
  • WO2007/015870 discloses certain polymorphs of nilotinib and pharmaceutically acceptable salts thereof useful for the present invention.
  • a preferred oral daily dosage of nilotinib is 200 - 1200 mg, e.g. 800 mg, administered as a single dose or divided into multiple doses, such as twice daily dosing.
  • the present invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-rnethyl- 3 ⁇ (4-pyridin-3-yl)pyrimidtn-2-yiamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-rnethy!-3-[(4-(3-pyridinyl)-2-pyrirnidinyl]amino]- ⁇ /-[5-(4-rnethyl-1 H-imidazol- 1-yl)-3-(trifluoromethyf) phenyl] benzamide or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of disorders mediated by alpha-carbonic anhydrase isoforms.
  • the present invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N- ⁇ 4-methyl-3- (4-pyridirv-3 ⁇ yl)pyrimidtn-2-yiamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, especially the mesylate salt, for the treatment of disorders mediated by aipha- carbontc anhydrase isoforms.
  • the present invention relates to 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyI]aminol- ⁇ /-[S-(4-methyl-1 H-imidazol-1 -yl)-3-(trifluoromethyl)phenylj benzamWe or a pharmaceutically acceptable salt thereof, especially the hydrochloride monohydrate, for the treatment of disorders mediated by alpha-carbonic anhydrase isoforms.
  • the present invention provides for 4-(4-methylpiperazin-1-yimethyl)-N-
  • the invention relates also to a method for administering to a mammal having a disorder mediated by alpha-carbonic anhydrase isoforms a pharmaceutically effective amount of imatinib or niiotinib or a pharmaceutically acceptable salt thereof, respectively, to the human subject.
  • the invention relates to the following combinations and their use for treating disorders mediated by alpha-carbonic anhydrase isoforms: (1) a combination comprising (a) imatinib or a pharmaceutically acceptable salt thereof and (b) at least one additional compound suitable for the treatment of one of the disorders mentioned herein,
  • the present invention relates to a combination comprising (a) 4-(4- methylpiperaan-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino) ⁇ henyl]- benzamide or a pharmaceutically acceptable sait thereof or (b) 4-methyl-3-[(4-(3-pyridinyl)-2- ⁇ yrfmidinyl)amtno]- ⁇ /- ⁇ S-(4-methyl-1H-imtdazol-1-yl)-3-(trifluoromethyl)phenyl] benzamid ⁇ or a pharmaceutically acceptable salt thereof and (c) at least one additional compound, the latter being suitable for the treatment of intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, headaches, neurological disorders and obesity.
  • intraocular hypertension glaucoma
  • epilepsy Lennox-Gastaut syndrome
  • altitude sickness headaches
  • Example 1 inhibition of the catalytlcally active mammalian CA i ⁇ oforms CA I - XV by imatinib and mlotimb
  • CA isozymes are recombinant ones obtained as reported earlier by (a) Pastorekova, S. et a!, J. Enz. Inhib. Med. Chem. 2004, 19, 199; (b) Supuran, CT. , Scozzafava, A. Bioorg. Med. Chem. 2007, 15, 4336; (c) Nishimori, I. et ai, Bioorg. Med. Chem. 2007, 15, 7229; (d) VuIIo, D. et al, Bioorg. Med. Chem. Lett. 2005, 15, 971; (e) Nishimori, I. et al, Bioorg. Med. Chem. Lett 2005, 15, 3828; (f) VuUo, D. et ai, Bioorg. Med. Chem. Lett. 2005, 15, 963.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2010/057598 2009-06-02 2010-06-01 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms Ceased WO2010139678A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012513590A JP2012528824A (ja) 2009-06-02 2010-06-01 アルファ−炭酸脱水酵素アイソフォームにより媒介される哺乳動物の障害の処置
EP10722356.2A EP2437745B1 (en) 2009-06-02 2010-06-01 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
US13/375,946 US9623025B2 (en) 2009-06-02 2010-06-01 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09161720.9 2009-06-02
EP09161720 2009-06-02

Publications (1)

Publication Number Publication Date
WO2010139678A1 true WO2010139678A1 (en) 2010-12-09

Family

ID=40902237

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2010/057598 Ceased WO2010139678A1 (en) 2009-06-02 2010-06-01 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
PCT/US2010/036836 Ceased WO2010141427A1 (en) 2009-06-02 2010-06-01 Treatment of ophthalmologic disorders mediated by albha-carbonic anhydrase isoforms

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2010/036836 Ceased WO2010141427A1 (en) 2009-06-02 2010-06-01 Treatment of ophthalmologic disorders mediated by albha-carbonic anhydrase isoforms

Country Status (5)

Country Link
US (1) US9623025B2 (https=)
EP (1) EP2437745B1 (https=)
JP (3) JP2012528824A (https=)
TW (2) TW201102068A (https=)
WO (2) WO2010139678A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520226A (ja) * 2012-06-18 2015-07-16 アジョウ・ユニバーシティ・インダストリー−アカデミック・コーポレイション・ファウンデイションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ イマチニブまたはこの薬学的に許容される塩を有効成分として含む血管透過性疾患の治療若しくは予防用組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
WO2018211474A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072090A2 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US8512738B2 (en) * 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
MX2009011226A (es) * 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
JP6623812B2 (ja) * 2016-02-17 2019-12-25 セイコーエプソン株式会社 位置検出装置、及び、そのコントラスト調整方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072090A2 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Tasigna (nilotinib) - Highlights of prescribing information", INTERNET CITATION, October 2007 (2007-10-01), pages 1 - 12, XP002542809, Retrieved from the Internet <URL:http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf> [retrieved on 20090825] *
BRECCIA M ET AL: "Ocular side effects in chronic myeloid leukemia patients treated with imatinib", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 32, no. 7, 1 July 2008 (2008-07-01), pages 1022 - 1025, XP022614166, ISSN: 0145-2126, [retrieved on 20071203] *
BROWNLOW N ET AL: "Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2008 LNKD- PUBMED:17851554, vol. 22, no. 3, March 2008 (2008-03-01), pages 649 - 652, XP002595640, ISSN: 1476-5551 *
CHICHE, J. ET AL., J, CANCER RES., vol. 69, 2009, pages 358
CLAUDIU T. SUPURAN: "Carbonic anhydrases: novel therapeutic applications for inhibitors and activators", NATURE REVIEWS DRUG DISCOVERY, vol. 7, February 2008 (2008-02-01), pages 168 - 181, XP002542810 *
DOGAN S S ET AL: "Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US LNKD- DOI:10.1016/J.HOC.2008.11.003, vol. 23, no. 1, 1 February 2009 (2009-02-01), pages 109 - 114, XP009121619, ISSN: 0889-8588 *
DUBOIS, L ET AL., RADIOTHER, ONCOL., vol. 83, 2007, pages 367
EBBESEN, P. ET AL., J. ENZYME LNHIB. MED. CHEM., vol. 24, no. 1, 2009, pages 1 - 39
HAAPASALO, J. ET AL., NEURO ONCOL., vol. 9, 2007, pages 308
HILVO, M. ET AL., J. BIOL. CHEM., vol. 283, 2008, pages 27799
JABBOUR ELIAS; CORTES JORGE; GILES FRANCIS; O'BRIEN SUSAN; KANTARIJAN HAGOP: "Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL, vol. 10, no. 7, 2007, pages 468 - 479, XP002542808 *
KHALIFAH, R. G., J. BIOL, CHEM., vol. 246, 1971, pages 2661
KORHONEN, K. ET AL., J. NEUROSURG., 13 February 2009 (2009-02-13)
LEPPILAMPI, M. ET AL., CLIN, CANCER, RES., vol. 8, 2002, pages 2240
LEPPILAMPI, M. ET AL., CLIN. CANCER. RES., 2002
MARESCA, A. ET AL., J. AM. CHEM. SOC., vol. 131, 2009, pages 3057
MOEN M D ET AL: "IMATINIB A REVIEW OF ITS USE IN CHRONIC MYELOID LEUKAEMIA", DRUGS, ADIS INTERNATIONAL LTD, vol. 67, no. 2, 1 January 2007 (2007-01-01), pages 299 - 320, XP008078847, ISSN: 0012-6667 *
NISHIMORI, I. ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 3828
NISHIMORI, I. ET AL., BIOORG. MED. CHEM., vol. 15, 2007, pages 7229
PARKKILA, S. ET AL., HISTOCHEM. J., vol. 27, 1995, pages 133
PASTOREKOVA, S. ET AL., J. ENZ. INHIB. MED. CHEM., vol. 19, 2004, pages 199
SEVINC ALPER: "Activity of Nilotinib (AMN-107) Alone in Advanced Gastrointestinal Stromal Tumors Progressing on Imatinib and Sunitinib Case Report", CHEMOTHERAPY, vol. 55, no. 2, February 2009 (2009-02-01), Switzerland, pages 132 - 136, XP002543527 *
SUPURAN CLAUDIU T. ; SCOZZAFAVA ANDREA ; CASINI ANGELA: "Carbonic anhydrase inhibitors", MEDICINAL RESEARCH REVIEWS, vol. 23, no. 2, 2003, Unitesd States, pages 146 - 189, XP002542811 *
SUPURAN, C.T. ET AL., MED. RES. REV., vol. 23, 2003, pages 146
SUPURAN, C.T., NAT. REV. DRUG DISCOV, vol. 7, 2008, pages 168
SUPURAN, C.T.; SCOZZAFAVA, A., BIOORG, MED. CHEM., vol. 15, 2007, pages 4336
SUPURAN, C.T.; SCOZZAFAVA, A.: "Carbonic anhydrase inhibitors and their therapeutic potential", EXPERT OPIN. THER. PAT., vol. 10, 2000, pages 575 - 600, XP001026091, DOI: doi:10.1517/13543776.10.5.575
SUPURAN, C.T.; SCOZZAFAVA, A; CASINI, A.: "Carbonic anhydrase inhibitors", MED. RES. REV., vol. 23, 2003, pages 146 - 183
SUPURAN, NATURE REV DRUG DISCOV, 2008
SVASTOVA, E. ET AL., FEBS LETT., vol. 577, 2004, pages 439
VULLO, D ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 971
VULLO, D. ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 983
YOSHIURA, K., CLIN CANCER RES., vol. 11, 2005, pages 820 1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520226A (ja) * 2012-06-18 2015-07-16 アジョウ・ユニバーシティ・インダストリー−アカデミック・コーポレイション・ファウンデイションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ イマチニブまたはこの薬学的に許容される塩を有効成分として含む血管透過性疾患の治療若しくは予防用組成物
US9511068B2 (en) 2012-06-18 2016-12-06 Ajou University Industry-Academic Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient

Also Published As

Publication number Publication date
JP2017203037A (ja) 2017-11-16
JP2016020375A (ja) 2016-02-04
TW201102068A (en) 2011-01-16
TWI565466B (zh) 2017-01-11
US9623025B2 (en) 2017-04-18
US20120088776A1 (en) 2012-04-12
TW201102069A (en) 2011-01-16
EP2437745B1 (en) 2017-08-23
EP2437745A1 (en) 2012-04-11
JP2012528824A (ja) 2012-11-15
WO2010141427A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
US9623025B2 (en) Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
AU2014372166B2 (en) Pharmaceutical combinations
US20150202203A1 (en) Method of Treating Gastrointestinal Stromal Tumors
CN103889422A (zh) 治疗胃肠道间质瘤的方法
JP5778735B2 (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
JP2019031517A (ja) 過剰増殖性疾患の治療のためのｍｅｋ阻害剤とｅｒｋ阻害剤の組合せの使用
WO2013063003A1 (en) Method of treating gastrointestinal stromal tumors
CN101106983A (zh) JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
TW202502325A (zh) 治療黑色素瘤的藥物組合的用途
JP2011530607A5 (https=)
Ziemska et al. Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy-characterisation of their inhibitors
TWI698238B (zh) Ｅｚｈ２抑制劑組合治療
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
NZ622155B2 (en) Method of treating gastrointestinal stromal tumors
US20230301973A1 (en) Treatment of diffuse intrinsic pontine glioma
HK40018465B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
WO2003090750A1 (en) Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera
HK1245640B (zh) 抗肿瘤剂的副作用减轻剂
TW201332551A (zh) 治療胃腸道基質瘤之方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722356

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012513590

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13375946

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2010722356

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010722356

Country of ref document: EP